{"ticker": {"uuid": "e078df99-e5c1-4092-8b99-9663f5257343", "symbol": "IPSC", "name": "Century Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses", "summary": "Century Therapeutics (NASDAQ:IPSC) will present data on its CNTY-813 iPSC-derived islet replacement therapy for type 1 diabetes at two upcoming scientific congresses in September and October 2026. The therapy, engineered with Allo-Evasion\u2122 5.0, aims for durable engraftment withou", "url": "https://finance.yahoo.com/healthcare/articles/century-therapeutics-ipsc-present-cnty-103348607.html", "source_name": "Market source", "published_at": "2026-07-14T10:40:46", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Century Therapeutics (IPSC) Declines 2.6% Amid Biotech Sector Pressure - Put Support", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOcXNGY2trYkNrQndqTHFfYTRERUtKZEtLVzhEOW5IQ3V4a1VlWkpyMlMxMkdVeGVIWG1uUzVOVVU5UUMyb3RyZTZQQ0xGWE1YaU5za1pjUV9Td0FweW80dU9zSE1IanhyV0NKbmUtMjNPLW4zWlJnaHhELXNiaTBWQVBDZWkwR1BWNGlvT0tvcGdtQWc0X1JRc2c1eWtwb3BPamx6djV2SjA3VzB3TmhlZEhaWURUWVk?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-12T00:47:45+00:00", "published_display": "12 Jul 2026 00:47", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPdjVfamJIV2laTjRMbUVkb0lzYXNqSTJYbjFYb3ptSlk2VVNCMkhfQXZCVEpBMDV3czROWnQ4b1dDa3p5R2liM3dicXFaRmRubDFsZnNodllBdnhzRzhFWGZYQzUzbzFqTW5lWUFzUkRQaTJMWHE0S2pWc2tqMVVYUUtDNmJEeEtnWUFFVHZiT01QR1E0ZGVtaWNmR3BROU0tWU9aOVFaMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T17:41:14+00:00", "published_display": "09 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D\u00ae Clinical & Research Congress 2026", "summary": "Century Therapeutics (NASDAQ: IPSC) announced that its CNTY-813 preclinical data abstracts have been accepted for oral presentations at two upcoming scientific congresses: the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan and the Breakt", "url": "https://investingnews.com/century-therapeutics-selected-for-oral-presentations-of-cnty-813-preclinical-data-at-easd-2026-and-breakthrough-t1d-r-clinical-research-congress-2026/", "source_name": "Investing News Network", "published_at": "2026-07-09T18:40:46", "published_display": "09 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics wins oral slots for CNTY-813 at two diabetes congresses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbWJpODFDMEVlSV9wSWpWQXRudlloekwzUTZlMXFPc01mdHpGY2Y1YmEwQnI2U0hUOXA1b19QYXF3aVFxTVNqcDN1c2lkdEJ4ZVFnS2dmRFh3OENCS0NJWGZWbkFJNXNEcmE2NjFUaHpxNHo5Rkg3TTItRnprZjVQN0MyandrVGhtcWNaekctOFFBVFdVVjV3eFJCWkZTRjA0T05FZ2lwNmtzVkMtcjd6TlRySV9SMkstSUJZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T12:00:00+00:00", "published_display": "09 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics abstracts accepted for diabetes conferences", "summary": "Century Therapeutics (NASDAQ: IPSC) announced that abstracts for its CNTY-813 therapy program for type 1 diabetes have been accepted for oral presentations at two upcoming diabetes conferences: the EASD 2026 and CRC 2026. The company is developing this induced pluripotent stem ce", "url": "https://www.investing.com/news/company-news/century-therapeutics-abstracts-accepted-for-diabetes-conferences-93CH-4783975", "source_name": "Investing.com", "published_at": "2026-07-09T12:11:22", "published_display": "09 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPSC - Century Therapeutics Inc Short Interest", "summary": "This article provides a detailed overview of Century Therapeutics Inc. (IPSC) stock, including its latest closing price, market capitalization, financial performance metrics, and key insider and institutional ownership data. It also highlights short interest, stock performance ov", "url": "https://finviz.com/stock?t=IPSC&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-07-04T12:10:44", "published_display": "04 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Century Therapeutics, Inc. \u2013 NASDAQ:IPSC", "summary": "This page provides financial information for Century Therapeutics, Inc. (NASDAQ: IPSC), specifically focusing on its price-to-sales forward metric. The content appears to be a financial data page from TradingView, offering an overview of the company's financials for investors.", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T16:39:33", "published_display": "02 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPSC News | CENTURY THERAPEUTICS INC (NASDAQ:IPSC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFB2UEpzYkN0NXdoLS1vQ1lOeUp2SkpqdkF4YXkxSXVXUl9aVm52dktpZWRBSER6cXQwOVFDR0VWT1JwblZpSmNhT1dUYk10NUR1Z2h6ZDlMMVBfNnM?oc=5", "source_name": "ChartMill", "published_at": "2026-07-01T00:01:41+00:00", "published_display": "01 Jul 2026 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark", "summary": "Century Therapeutics, Inc. (NasdaqCM: IPSC) has been included in the Russell 2000 Value Benchmark. The company, a biotechnology firm, focuses on developing allogeneic cell therapies for various diseases, including solid tumors, hematological malignancies, and autoimmune condition", "url": "https://www.marketscreener.com/news/century-therapeutics-inc-nasdaqcm-ipsc-added-to-russell-2000-value-benchmark-ce7f5fdfd88cf221", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:15:46", "published_display": "29 Jun 2026 15:15", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index", "summary": "Century Therapeutics, Inc. (NasdaqCM: IPSC), a biotechnology company focused on allogeneic cell therapies, has been added to the Russell Microcap Index. The announcement highlights the company's progress in developing treatments for solid tumor and hematological malignancies, as ", "url": "https://www.marketscreener.com/news/century-therapeutics-inc-nasdaqcm-ipsc-added-to-russell-microcap-index-ce7f5fdedd89fe24", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:10:11", "published_display": "29 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNTnd1MlNYdHpXaXRwemcyZG9QYTdBa2ttdkIzOGpFc2U4QUt2VW9TcDNPXzM1V241bkVfaWVaeG94SzlEVDFsMnJyWVl0NUFhaGZPOWdRTGdvckplNHVIT0F5em9CeDlnTU5qMXQxb2dGRFNITDhxai1JNjBFMjByNV85R2Z2eHJ0bGI1aTEySm5YaE9aOTlpZzlqem9RUERlWExZT0hlbkRtLVRHeEk0U1duZl9GZjRZaHF3LTJhZk1SWnRPcDZ3RHlR?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC)", "summary": "This article provides an overview of Century Therapeutics, Inc. (NASDAQ: IPSC) stock, including its current price, performance trends, analyst forecasts, and financial data. It details the company's market capitalization, earnings, revenue, and EBITDA, while also offering guidanc", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:08:58", "published_display": "26 Jun 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Century Therapeutics, Inc. \u2013 NASDAQ:IPSC", "summary": "This article provides financial information for Century Therapeutics, Inc. (NASDAQ: IPSC) on TradingView. It specifically highlights the company's enterprise value to EBIT forward. The content is primarily a financial data page from TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:51", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Century Therapeutics, Inc. \u2013 NASDAQ:IPSC", "summary": "This article provides a brief financial overview of Century Therapeutics, Inc. (NASDAQ: IPSC) specifically focusing on its forward price-to-earnings ratio. It indicates that as of the market close, there were no trades recorded for the company's stock. The content is primarily a ", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T07:39:17", "published_display": "26 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Century Therapeutics, Inc. \u2013 NASDAQ:IPSC", "summary": "This article provides forward-looking enterprise value to revenue data for Century Therapeutics, Inc. (NASDAQ: IPSC) sourced from TradingView. The financial data and market information are presented within the context of a market data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:12:18", "published_display": "25 Jun 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Century Therapeutics Inc (IPSC) has a financial score of 8.26, ranking 53rd in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. Despite this, the company reported a 100% year-over-year decrease in its latest quarterl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipsc/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T06:39:53", "published_display": "19 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Century Therapeutics Inc (IPSC), highlighting its current valuation score, P/E ratio, and market performance. The company has a current valuation score of 6.56, ranking 317 out of 388 in the Biotechnology & Medical Research industry, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipsc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T06:40:33", "published_display": "17 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics amends chief scientific officer contract to part-time role", "summary": "Century Therapeutics has amended its chief scientific officer, Dr. Chad Cowan's, employment agreement to a part-time role, reducing his annual salary to $296,150 while he remains eligible for a pro-rated performance-based bonus. This move comes as the company, whose stock has sur", "url": "https://www.investing.com/news/sec-filings/century-therapeutics-amends-chief-scientific-officer-contract-to-parttime-role-93CH-4745701", "source_name": "Investing.com", "published_at": "2026-06-16T21:40:33", "published_display": "16 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms", "summary": "Century Therapeutics (IPSC) has updated the employment terms for its Chief Scientific Officer, Chad Cowan, Ph.D., transitioning him to a part-time role. Under the new agreement, Dr. Cowan's annual salary will be $296,150, and he will remain eligible for a pro-rated performance-ba", "url": "https://www.stocktitan.net/sec-filings/IPSC/8-k-century-therapeutics-inc-reports-material-event-bfbaacab11c5.html", "source_name": "Stock Titan", "published_at": "2026-06-16T19:40:33", "published_display": "16 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com", "summary": "Gregory Russotti, Chief Technology and Manufacturing Officer at Century Therapeutics (NASDAQ: IPSC), sold 2,584 shares of company stock worth $5,767 on June 12, 2026. This transaction was automatic and intended to cover tax withholding obligations related to restricted stock unit", "url": "https://ng.investing.com/news/insider-trading-news/century-therapeutics-executive-gregory-russotti-sells-5767-in-stock-93CH-2559557", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T08:10:10", "published_display": "16 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com", "summary": "Douglas Carr, SVP of Finance & Operations at Century Therapeutics (NASDAQ:IPSC), sold 1,654 shares worth $3,691 to cover tax withholding related to restricted stock unit vesting. The company's stock is up nearly 300% over the past year, and it recently presented positive preclini", "url": "https://m.au.investing.com/news/insider-trading-news/century-therapeutics-svp-carr-sells-3691-in-company-stock-93CH-4488763?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-16T01:10:24", "published_display": "16 Jun 2026 01:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related share sale by Century Therapeutics (IPSC) SVP Carr", "summary": "Douglas Carr, Senior Vice President of Finance and Operations at Century Therapeutics (IPSC), automatically sold 1,654 shares of common stock at $2.232 per share on June 12, 2026. This transaction was conducted to cover tax withholding obligations associated with the vesting of r", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-d9e4a83effd4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:10:24", "published_display": "16 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding", "summary": "Century Therapeutics executive Gregory Russotti sold 2,584 shares of common stock at an average price of $2.232 to cover tax withholding obligations related to restricted stock unit vesting. These sales were automatic and not at Russotti's discretion. After the transaction, he di", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-0681c69e6a5c.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:10:24", "published_display": "16 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings", "summary": "Century Therapeutics' Chief Scientific Officer, Chad Cowan, reported a routine share activity where 358 common shares were withheld at $2.24 each to cover tax obligations following the vesting of restricted stock units. This was not an open-market sale. After this transaction, Co", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-f7aa87e12be2.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:10:24", "published_display": "16 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting", "summary": "Century Therapeutics' President and CEO, Brent Pfeiffenberger, reported a tax-related disposition of 13,849 shares of Common Stock. These shares, valued at $2.24 each, were withheld by the company to satisfy tax obligations upon the vesting of restricted stock units (RSUs). This ", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-97846e1b571a.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:10:24", "published_display": "16 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics SVP Carr sells $3,691 in company stock", "summary": "Douglas Carr, SVP of Finance & Operations at Century Therapeutics, Inc. (NASDAQ: IPSC), sold 1,654 shares of company stock worth $3,691 on June 12, 2026. The sale was executed to cover tax withholding obligations related to restricted stock units. After the transaction, Carr dire", "url": "https://www.investing.com/news/insider-trading-news/century-therapeutics-svp-carr-sells-3691-in-company-stock-93CH-4743648", "source_name": "Investing.com", "published_at": "2026-06-15T23:39:26", "published_display": "15 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-were-watching-century-133825514.html", "source_name": "Simply Wall St.", "published_at": "2026-06-13T13:38:25+00:00", "published_display": "13 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) director receives grant of 74,000 stock options", "summary": "Century Therapeutics director Martin Patrick Murphy was granted 74,000 stock options with an exercise price of $2.24 per share, expiring on June 11, 2036. These options will vest on June 11, 2027, or the next annual meeting of stockholders, contingent on his continued service. Th", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-1d8a7c5686f7.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:47", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24", "summary": "Century Therapeutics (IPSC) director Lee Han Myung was granted 74,000 stock options with an exercise price of $2.24, expiring on June 11, 2036. The options will vest on the earlier of June 11, 2027, or the company's next annual meeting, provided Lee Han Myung continues his servic", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-97c193bb43bb.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:13", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell", "summary": "Century Therapeutics (IPSC) has granted its director, Kimberly Blackwell, a stock option award for 74,000 shares of common stock. These options have an exercise price of $2.24 per share and are set to expire on June 11, 2036. The shares will vest on the earlier of June 11, 2027, ", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-e3bca9c5fdf3.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:13", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options", "summary": "Century Therapeutics (IPSC) director Alessandro Riva was granted 74,000 stock options as compensation, allowing him to purchase common stock at an exercise price of $2.24 per share. These options expire on June 11, 2036, and will vest on the earlier of June 11, 2027, or the next ", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-261df86d67c0.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:13", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate", "summary": "Century Therapeutics (IPSC) stockholders approved an increase in authorized common shares from 300,000,000 to 450,000,000, effective June 12, 2026. At the same annual meeting, shareholders elected Alessandro Riva and Han Lee as Class II directors, serving until the 2029 Annual Me", "url": "https://www.stocktitan.net/sec-filings/IPSC/8-k-century-therapeutics-inc-reports-material-event-ff28c10a17d9.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:13", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/century-therapeutics-ipsc-reports-positive-182249219.html", "source_name": "Insider Monkey", "published_at": "2026-06-10T18:22:49+00:00", "published_display": "10 Jun 2026 18:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Initiates Century Therapeutics at Outperform", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mizuho-initiates-century-therapeutics-outperform-105626269.html", "source_name": "MT Newswires", "published_at": "2026-06-04T10:56:26+00:00", "published_display": "04 Jun 2026 10:56", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Mizuho Initiates Century Therapeutics at Outperform With $8 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-initiates-century-therapeutics-outperform-105424378.html", "source_name": "MT Newswires", "published_at": "2026-05-27T10:54:24+00:00", "published_display": "27 May 2026 10:54", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Century Therapeutics Reports First Quarter Financial Results and Business Updates", "summary": "", "url": "https://finance.yahoo.com/news/century-therapeutics-reports-first-quarter-120000649.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:00:00+00:00", "published_display": "13 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQS29pTFpGaHFzeXlGRDA3bFZHWnJjMm5NemVWaUVrTHczV1Q5ODRRNkt1MEwyNDJiWHM4cnRzblNwQ0tzc3o2TG9CU0w0bnVqWlFRSlJVdjA3QXZuNTUxMTBQZVlTWTlUSzJ2Tk14TkxWTXVfbV90WkJqSDVza3U4QWFBNW5yaHlMOTQzWVhwb00yeWpSeUVlZ3VRdUNZc0dp?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPUDlSSnVzQjVhaWkzWXBzMHY5VUFfcE5oQTI1amNBWV9Hb2lTX3ZacE5nR28zelI1QXdhY1RlOGVYM29KWDNtZXBfTWVhdFZwU09QdDN2OWdtRlB2RGMwX1BfZ25iRkJ3M3hSOXdmWWZaVnhCZVFSblNEVjk5cC1HWlNCMU00UkkzVDhWQk9RWWNXUlBHeWF1Uzd6SHN4YUVxNG1MS1ZCWmc3cjBuelFkY29FQlVEUzVyUkp5Tw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNOXdZNTFXX3UxTXpNdlFzVjlKY2ZzbkhMVTNTQ19ueGl1SHRiT0o4N3B2bzJHZDdqN0Q0SDk1VlNOQURZMnozYWk0TjRSS0xKZXhQOE82MmdkRmNVVVlpVVctWXplOFAwbHdLSzlKbFg2bmdCQlA5enY4SGRlWC1rOGNVYW84LTQwbVR3Q3pCMFZvblg4Qmc?oc=5", "source_name": "Market source", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc. Common Stock (IPSC) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1zdlR0SlJ6VVk2RXFaQk1zYnBmWVFPXzMyb1R1WjA5alMtcmVWMjc5Nm5ZLUpUV1QzYkFSd19YV0ZBTjdzVlhmczR2UUFhbUFDVmNrSWNiSQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-15T01:06:38+00:00", "published_display": "15 Jan 2026 01:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics set to close $135M raise to advance Type 1 diabetes cure", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOMU5zeDZqY0hFUGlGMjU2d1dJZlBqUG43ZDVLa1c2Y3FfTVM1WUI1Q213MHZJWG9nVEFQRTcxYUxyS1daV29OWHdGLXBiaVlUTUN5aW85VEFQUjF0dlJFbUtRUVlNdnZzYjlvOWtmY2dGaU1RcHEwM0t2VDlSbmpKTndMUHdfekV4RGFSZDhkVEplZ1JzZXB3c0NiTEdXeHMwX0xxb0hmY3NhX1F3?oc=5", "source_name": "The Business Journals", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Inc. (IPSC) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1UMU9VLVNBdXBGd0tkOWR3Q2p5VXJTSER5bVE4UzBSU1BRdFJWZjZiY19PRGhwMzh5cm90SG5TRm5DVHJGMURXSTJfTFJ3dw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-01-08T15:18:10+00:00", "published_display": "08 Jan 2026 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxQczhMdHJMWmtlTjhiWEVrNnM3QThaczBheGJoZDV2blIzV3VENklMVkJxeWxqQThwMGRJVF9rWXp1ZUVDTThhTURvcno2dHBsd0VmZVlXUjlBa3hscGswQ0FHRXhHQzZzdlhxdGk0c2wxZGMxRkNkejlLdm1jaE9ER3VtOTZiaXE2eGE4cFpiaTljS3dLclhqY0cyOE1ETlJ2Q3AwNWg1d3RMWHFTd25jcm1aNjlOYVhLSG5qX1EtVnl2N3oydDFpbmRjV0ppU1lwTkFFYzlxaG55Y1FZLUdlQ2tndG8zSHJYOV8wZjR4ZnVwYml2VjNTbUx5bWJfZmZySnV3ejU2OUpXSVBwMFpXRXM4RU5XdG5nS1lvbEsxdw?oc=5", "source_name": "Investing News Network", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics secures $135 million in private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNQnRsSU50ZUR1LXRSdnBQeV8yMl9tTjMtUlp4N0xfQWhyeXpKd1FqRlNWYmZCUEFfbDB1MEhiZFh3eWNhdG13ckdsbzV5cm51amhBOWlPZnV1Vm9OQ1BmSThTWUd6WktPb3NUdlVkdUVobWJVSUZBUi1FdDZtM29WdjJjWW1SbGllcjNNeVBDS0ZJMTB2RUhjT1ZTYS1OZVlxRWRlM25yT0I1c05jSUNhaWhpcTBIcHhDM1E?oc=5", "source_name": "Investing.com", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNTGh1Y1paWm1ycmFDX3dtazh2Tlo4cENibnBHd2dVRTBlekc4SXdNdVlNdWZJWDZHR2czdWxrTWwyZlVKZlFqbjJYQmwxRzlORUFodEs3MHB3VTRYTnNMM29TVnRSUFZIYUxyLXp4cmNtaEIwdUFrcWZ3U0JtZXNlVVZjNm1pdw?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc._December 31, 2024", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNUWQxUmtfNFg0bWpqR0RRMkc0Z0J5ckwyb1Y5UEk0MUhYXzJuSXpjck5meUhlQ2J1by1kMlI0NmRfdm1SazlORHpNYkdkcllOUVFpdDJRbkdTcG8zdGFFVldtSEVjZV93blFJTjNHNFVUenpRVHdfSWpfY3F6M0xnTDVZVkcwYWlaWG1mWHVpRDBMUQ?oc=5", "source_name": "SEC.gov", "published_at": "2025-03-21T00:59:10+00:00", "published_display": "21 Mar 2025 00:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Raises $60 Million, Acquires Clade Therapeutics, and Expands Pipeline of Allogeneic, iPSC-Derived Cellular Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNM1Q2MTBxMzJUcTRZcF9HMTJlWGJ4alVDNXd1UWhTNWttMEdPU2s5dzRFcnBQWmxNQ05yT0dqMXlrLU1YQlZuaHoxODFfSkxIMW5aSGxCRlk0WlpjNXk2ZVZCWjRkMzV4U3VoODl4MTR3NUxnRlA5X0FESEk3QnpXV2dIYVBMQTjSAYwBQVVfeXFMTlNrTDVCdlpiQmxNM2xuOFBBT1hydEtMdDk2QzEycEhKZk41d1BBRGowSUxBTjdpM3haQWNGbnYtZlJETWwzLVNIeE1MRjhZSFpEcU5jNUtRQTdiYTE2VjZ4WnRJTnpPeWdJWUtmYTVsUy1pN1RFQ1JyaWc2M3k5VkNCYUVWZWhvckd6N3E?oc=5", "source_name": "BioInformant", "published_at": "2024-05-05T07:00:00+00:00", "published_display": "05 May 2024 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE1MRUNUeTBETy1xaWNWazJ0eHVURWdTYXVtMTVUNXlybVlmZjgtSjJHUkhzS01CdWpsY3NJTERHWUZPS1NJNVRUMTZveU9WOEU?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-06-21T01:51:48+00:00", "published_display": "21 Jun 2021 01:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) Stock Price, News & Analysis $IPSC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBMNHhhMThYY2l6elk4Ykx1dzM2cHRGNHlwY0E4QXRRZXRGckFueDUwYUt2OU1uZGpXMklJZm0yNzJRRHFlUGY1WndLVl93UUNBcGVQLU55c09LZw?oc=5", "source_name": "MarketBeat", "published_at": "2021-06-19T00:01:24+00:00", "published_display": "19 Jun 2021 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses", "summary": "Century Therapeutics (NASDAQ:IPSC) will present data on its CNTY-813 iPSC-derived islet replacement therapy for type 1 diabetes at two upcoming scientific congresses in September and October 2026. The therapy, engineered with Allo-Evasion\u2122 5.0, aims for durable engraftment withou", "url": "https://finance.yahoo.com/healthcare/articles/century-therapeutics-ipsc-present-cnty-103348607.html", "source_name": "Market source", "published_at": "2026-07-14T10:40:46", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) Declines 2.6% Amid Biotech Sector Pressure - Put Support", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOcXNGY2trYkNrQndqTHFfYTRERUtKZEtLVzhEOW5IQ3V4a1VlWkpyMlMxMkdVeGVIWG1uUzVOVVU5UUMyb3RyZTZQQ0xGWE1YaU5za1pjUV9Td0FweW80dU9zSE1IanhyV0NKbmUtMjNPLW4zWlJnaHhELXNiaTBWQVBDZWkwR1BWNGlvT0tvcGdtQWc0X1JRc2c1eWtwb3BPamx6djV2SjA3VzB3TmhlZEhaWURUWVk?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-12T00:47:45+00:00", "published_display": "12 Jul 2026 00:47", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPdjVfamJIV2laTjRMbUVkb0lzYXNqSTJYbjFYb3ptSlk2VVNCMkhfQXZCVEpBMDV3czROWnQ4b1dDa3p5R2liM3dicXFaRmRubDFsZnNodllBdnhzRzhFWGZYQzUzbzFqTW5lWUFzUkRQaTJMWHE0S2pWc2tqMVVYUUtDNmJEeEtnWUFFVHZiT01QR1E0ZGVtaWNmR3BROU0tWU9aOVFaMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-09T17:41:14+00:00", "published_display": "09 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D\u00ae Clinical & Research Congress 2026", "summary": "Century Therapeutics (NASDAQ: IPSC) announced that its CNTY-813 preclinical data abstracts have been accepted for oral presentations at two upcoming scientific congresses: the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan and the Breakt", "url": "https://investingnews.com/century-therapeutics-selected-for-oral-presentations-of-cnty-813-preclinical-data-at-easd-2026-and-breakthrough-t1d-r-clinical-research-congress-2026/", "source_name": "Investing News Network", "published_at": "2026-07-09T18:40:46", "published_display": "09 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics wins oral slots for CNTY-813 at two diabetes congresses", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNbWJpODFDMEVlSV9wSWpWQXRudlloekwzUTZlMXFPc01mdHpGY2Y1YmEwQnI2U0hUOXA1b19QYXF3aVFxTVNqcDN1c2lkdEJ4ZVFnS2dmRFh3OENCS0NJWGZWbkFJNXNEcmE2NjFUaHpxNHo5Rkg3TTItRnprZjVQN0MyandrVGhtcWNaekctOFFBVFdVVjV3eFJCWkZTRjA0T05FZ2lwNmtzVkMtcjd6TlRySV9SMkstSUJZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T12:00:00+00:00", "published_display": "09 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics abstracts accepted for diabetes conferences", "summary": "Century Therapeutics (NASDAQ: IPSC) announced that abstracts for its CNTY-813 therapy program for type 1 diabetes have been accepted for oral presentations at two upcoming diabetes conferences: the EASD 2026 and CRC 2026. The company is developing this induced pluripotent stem ce", "url": "https://www.investing.com/news/company-news/century-therapeutics-abstracts-accepted-for-diabetes-conferences-93CH-4783975", "source_name": "Investing.com", "published_at": "2026-07-09T12:11:22", "published_display": "09 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPSC - Century Therapeutics Inc Short Interest", "summary": "This article provides a detailed overview of Century Therapeutics Inc. (IPSC) stock, including its latest closing price, market capitalization, financial performance metrics, and key insider and institutional ownership data. It also highlights short interest, stock performance ov", "url": "https://finviz.com/stock?t=IPSC&p=d&ty=si", "source_name": "Finviz", "published_at": "2026-07-04T12:10:44", "published_display": "04 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Century Therapeutics, Inc. \u2013 NASDAQ:IPSC", "summary": "This page provides financial information for Century Therapeutics, Inc. (NASDAQ: IPSC), specifically focusing on its price-to-sales forward metric. The content appears to be a financial data page from TradingView, offering an overview of the company's financials for investors.", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T16:39:33", "published_display": "02 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IPSC News | CENTURY THERAPEUTICS INC (NASDAQ:IPSC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFB2UEpzYkN0NXdoLS1vQ1lOeUp2SkpqdkF4YXkxSXVXUl9aVm52dktpZWRBSER6cXQwOVFDR0VWT1JwblZpSmNhT1dUYk10NUR1Z2h6ZDlMMVBfNnM?oc=5", "source_name": "ChartMill", "published_at": "2026-07-01T00:01:41+00:00", "published_display": "01 Jul 2026 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark", "summary": "Century Therapeutics, Inc. (NasdaqCM: IPSC) has been included in the Russell 2000 Value Benchmark. The company, a biotechnology firm, focuses on developing allogeneic cell therapies for various diseases, including solid tumors, hematological malignancies, and autoimmune condition", "url": "https://www.marketscreener.com/news/century-therapeutics-inc-nasdaqcm-ipsc-added-to-russell-2000-value-benchmark-ce7f5fdfd88cf221", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:15:46", "published_display": "29 Jun 2026 15:15", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index", "summary": "Century Therapeutics, Inc. (NasdaqCM: IPSC), a biotechnology company focused on allogeneic cell therapies, has been added to the Russell Microcap Index. The announcement highlights the company's progress in developing treatments for solid tumor and hematological malignancies, as ", "url": "https://www.marketscreener.com/news/century-therapeutics-inc-nasdaqcm-ipsc-added-to-russell-microcap-index-ce7f5fdedd89fe24", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:10:11", "published_display": "29 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 3000E Value Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNTnd1MlNYdHpXaXRwemcyZG9QYTdBa2ttdkIzOGpFc2U4QUt2VW9TcDNPXzM1V241bkVfaWVaeG94SzlEVDFsMnJyWVl0NUFhaGZPOWdRTGdvckplNHVIT0F5em9CeDlnTU5qMXQxb2dGRFNITDhxai1JNjBFMjByNV85R2Z2eHJ0bGI1aTEySm5YaE9aOTlpZzlqem9RUERlWExZT0hlbkRtLVRHeEk0U1duZl9GZjRZaHF3LTJhZk1SWnRPcDZ3RHlR?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC)", "summary": "This article provides an overview of Century Therapeutics, Inc. (NASDAQ: IPSC) stock, including its current price, performance trends, analyst forecasts, and financial data. It details the company's market capitalization, earnings, revenue, and EBITDA, while also offering guidanc", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:08:58", "published_display": "26 Jun 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Century Therapeutics, Inc. \u2013 NASDAQ:IPSC", "summary": "This article provides financial information for Century Therapeutics, Inc. (NASDAQ: IPSC) on TradingView. It specifically highlights the company's enterprise value to EBIT forward. The content is primarily a financial data page from TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:51", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Century Therapeutics, Inc. \u2013 NASDAQ:IPSC", "summary": "This article provides a brief financial overview of Century Therapeutics, Inc. (NASDAQ: IPSC) specifically focusing on its forward price-to-earnings ratio. It indicates that as of the market close, there were no trades recorded for the company's stock. The content is primarily a ", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T07:39:17", "published_display": "26 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Century Therapeutics, Inc. \u2013 NASDAQ:IPSC", "summary": "This article provides forward-looking enterprise value to revenue data for Century Therapeutics, Inc. (NASDAQ: IPSC) sourced from TradingView. The financial data and market information are presented within the context of a market data platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-IPSC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:12:18", "published_display": "25 Jun 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Century Therapeutics Inc (IPSC) has a financial score of 8.26, ranking 53rd in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. Despite this, the company reported a 100% year-over-year decrease in its latest quarterl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipsc/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T06:39:53", "published_display": "19 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Century Therapeutics Inc (IPSC), highlighting its current valuation score, P/E ratio, and market performance. The company has a current valuation score of 6.56, ranking 317 out of 388 in the Biotechnology & Medical Research industry, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ipsc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T06:40:33", "published_display": "17 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics amends chief scientific officer contract to part-time role", "summary": "Century Therapeutics has amended its chief scientific officer, Dr. Chad Cowan's, employment agreement to a part-time role, reducing his annual salary to $296,150 while he remains eligible for a pro-rated performance-based bonus. This move comes as the company, whose stock has sur", "url": "https://www.investing.com/news/sec-filings/century-therapeutics-amends-chief-scientific-officer-contract-to-parttime-role-93CH-4745701", "source_name": "Investing.com", "published_at": "2026-06-16T21:40:33", "published_display": "16 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms", "summary": "Century Therapeutics (IPSC) has updated the employment terms for its Chief Scientific Officer, Chad Cowan, Ph.D., transitioning him to a part-time role. Under the new agreement, Dr. Cowan's annual salary will be $296,150, and he will remain eligible for a pro-rated performance-ba", "url": "https://www.stocktitan.net/sec-filings/IPSC/8-k-century-therapeutics-inc-reports-material-event-bfbaacab11c5.html", "source_name": "Stock Titan", "published_at": "2026-06-16T19:40:33", "published_display": "16 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com", "summary": "Gregory Russotti, Chief Technology and Manufacturing Officer at Century Therapeutics (NASDAQ: IPSC), sold 2,584 shares of company stock worth $5,767 on June 12, 2026. This transaction was automatic and intended to cover tax withholding obligations related to restricted stock unit", "url": "https://ng.investing.com/news/insider-trading-news/century-therapeutics-executive-gregory-russotti-sells-5767-in-stock-93CH-2559557", "source_name": "Investing.com Nigeria", "published_at": "2026-06-16T08:10:10", "published_display": "16 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com", "summary": "Douglas Carr, SVP of Finance & Operations at Century Therapeutics (NASDAQ:IPSC), sold 1,654 shares worth $3,691 to cover tax withholding related to restricted stock unit vesting. The company's stock is up nearly 300% over the past year, and it recently presented positive preclini", "url": "https://m.au.investing.com/news/insider-trading-news/century-therapeutics-svp-carr-sells-3691-in-company-stock-93CH-4488763?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-16T01:10:24", "published_display": "16 Jun 2026 01:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related share sale by Century Therapeutics (IPSC) SVP Carr", "summary": "Douglas Carr, Senior Vice President of Finance and Operations at Century Therapeutics (IPSC), automatically sold 1,654 shares of common stock at $2.232 per share on June 12, 2026. This transaction was conducted to cover tax withholding obligations associated with the vesting of r", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-d9e4a83effd4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:10:24", "published_display": "16 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding", "summary": "Century Therapeutics executive Gregory Russotti sold 2,584 shares of common stock at an average price of $2.232 to cover tax withholding obligations related to restricted stock unit vesting. These sales were automatic and not at Russotti's discretion. After the transaction, he di", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-0681c69e6a5c.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:10:24", "published_display": "16 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings", "summary": "Century Therapeutics' Chief Scientific Officer, Chad Cowan, reported a routine share activity where 358 common shares were withheld at $2.24 each to cover tax obligations following the vesting of restricted stock units. This was not an open-market sale. After this transaction, Co", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-f7aa87e12be2.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:10:24", "published_display": "16 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting", "summary": "Century Therapeutics' President and CEO, Brent Pfeiffenberger, reported a tax-related disposition of 13,849 shares of Common Stock. These shares, valued at $2.24 each, were withheld by the company to satisfy tax obligations upon the vesting of restricted stock units (RSUs). This ", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-97846e1b571a.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:10:24", "published_display": "16 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics SVP Carr sells $3,691 in company stock", "summary": "Douglas Carr, SVP of Finance & Operations at Century Therapeutics, Inc. (NASDAQ: IPSC), sold 1,654 shares of company stock worth $3,691 on June 12, 2026. The sale was executed to cover tax withholding obligations related to restricted stock units. After the transaction, Carr dire", "url": "https://www.investing.com/news/insider-trading-news/century-therapeutics-svp-carr-sells-3691-in-company-stock-93CH-4743648", "source_name": "Investing.com", "published_at": "2026-06-15T23:39:26", "published_display": "15 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/heres-why-were-watching-century-133825514.html", "source_name": "Simply Wall St.", "published_at": "2026-06-13T13:38:25+00:00", "published_display": "13 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) director receives grant of 74,000 stock options", "summary": "Century Therapeutics director Martin Patrick Murphy was granted 74,000 stock options with an exercise price of $2.24 per share, expiring on June 11, 2036. These options will vest on June 11, 2027, or the next annual meeting of stockholders, contingent on his continued service. Th", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-1d8a7c5686f7.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:47", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24", "summary": "Century Therapeutics (IPSC) director Lee Han Myung was granted 74,000 stock options with an exercise price of $2.24, expiring on June 11, 2036. The options will vest on the earlier of June 11, 2027, or the company's next annual meeting, provided Lee Han Myung continues his servic", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-97c193bb43bb.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:13", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell", "summary": "Century Therapeutics (IPSC) has granted its director, Kimberly Blackwell, a stock option award for 74,000 shares of common stock. These options have an exercise price of $2.24 per share and are set to expire on June 11, 2036. The shares will vest on the earlier of June 11, 2027, ", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-e3bca9c5fdf3.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:13", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options", "summary": "Century Therapeutics (IPSC) director Alessandro Riva was granted 74,000 stock options as compensation, allowing him to purchase common stock at an exercise price of $2.24 per share. These options expire on June 11, 2036, and will vest on the earlier of June 11, 2027, or the next ", "url": "https://www.stocktitan.net/sec-filings/IPSC/form-4-century-therapeutics-inc-insider-trading-activity-261df86d67c0.html", "source_name": "Stock Titan", "published_at": "2026-06-12T21:09:13", "published_display": "12 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate", "summary": "Century Therapeutics (IPSC) stockholders approved an increase in authorized common shares from 300,000,000 to 450,000,000, effective June 12, 2026. At the same annual meeting, shareholders elected Alessandro Riva and Han Lee as Class II directors, serving until the 2029 Annual Me", "url": "https://www.stocktitan.net/sec-filings/IPSC/8-k-century-therapeutics-inc-reports-material-event-ff28c10a17d9.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:13", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/century-therapeutics-ipsc-reports-positive-182249219.html", "source_name": "Insider Monkey", "published_at": "2026-06-10T18:22:49+00:00", "published_display": "10 Jun 2026 18:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Initiates Century Therapeutics at Outperform", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/mizuho-initiates-century-therapeutics-outperform-105626269.html", "source_name": "MT Newswires", "published_at": "2026-06-04T10:56:26+00:00", "published_display": "04 Jun 2026 10:56", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Mizuho Initiates Century Therapeutics at Outperform With $8 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-initiates-century-therapeutics-outperform-105424378.html", "source_name": "MT Newswires", "published_at": "2026-05-27T10:54:24+00:00", "published_display": "27 May 2026 10:54", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Reports First Quarter Financial Results and Business Updates", "summary": "", "url": "https://finance.yahoo.com/news/century-therapeutics-reports-first-quarter-120000649.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T12:00:00+00:00", "published_display": "13 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQS29pTFpGaHFzeXlGRDA3bFZHWnJjMm5NemVWaUVrTHczV1Q5ODRRNkt1MEwyNDJiWHM4cnRzblNwQ0tzc3o2TG9CU0w0bnVqWlFRSlJVdjA3QXZuNTUxMTBQZVlTWTlUSzJ2Tk14TkxWTXVfbV90WkJqSDVza3U4QWFBNW5yaHlMOTQzWVhwb00yeWpSeUVlZ3VRdUNZc0dp?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPUDlSSnVzQjVhaWkzWXBzMHY5VUFfcE5oQTI1amNBWV9Hb2lTX3ZacE5nR28zelI1QXdhY1RlOGVYM29KWDNtZXBfTWVhdFZwU09QdDN2OWdtRlB2RGMwX1BfZ25iRkJ3M3hSOXdmWWZaVnhCZVFSblNEVjk5cC1HWlNCMU00UkkzVDhWQk9RWWNXUlBHeWF1Uzd6SHN4YUVxNG1MS1ZCWmc3cjBuelFkY29FQlVEUzVyUkp5Tw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNOXdZNTFXX3UxTXpNdlFzVjlKY2ZzbkhMVTNTQ19ueGl1SHRiT0o4N3B2bzJHZDdqN0Q0SDk1VlNOQURZMnozYWk0TjRSS0xKZXhQOE82MmdkRmNVVVlpVVctWXplOFAwbHdLSzlKbFg2bmdCQlA5enY4SGRlWC1rOGNVYW84LTQwbVR3Q3pCMFZvblg4Qmc?oc=5", "source_name": "Market source", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc. Common Stock (IPSC) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1zdlR0SlJ6VVk2RXFaQk1zYnBmWVFPXzMyb1R1WjA5alMtcmVWMjc5Nm5ZLUpUV1QzYkFSd19YV0ZBTjdzVlhmczR2UUFhbUFDVmNrSWNiSQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-15T01:06:38+00:00", "published_display": "15 Jan 2026 01:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics set to close $135M raise to advance Type 1 diabetes cure", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOMU5zeDZqY0hFUGlGMjU2d1dJZlBqUG43ZDVLa1c2Y3FfTVM1WUI1Q213MHZJWG9nVEFQRTcxYUxyS1daV29OWHdGLXBiaVlUTUN5aW85VEFQUjF0dlJFbUtRUVlNdnZzYjlvOWtmY2dGaU1RcHEwM0t2VDlSbmpKTndMUHdfekV4RGFSZDhkVEplZ1JzZXB3c0NiTEdXeHMwX0xxb0hmY3NhX1F3?oc=5", "source_name": "The Business Journals", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Inc. (IPSC) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1UMU9VLVNBdXBGd0tkOWR3Q2p5VXJTSER5bVE4UzBSU1BRdFJWZjZiY19PRGhwMzh5cm90SG5TRm5DVHJGMURXSTJfTFJ3dw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-01-08T15:18:10+00:00", "published_display": "08 Jan 2026 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwJBVV95cUxQczhMdHJMWmtlTjhiWEVrNnM3QThaczBheGJoZDV2blIzV3VENklMVkJxeWxqQThwMGRJVF9rWXp1ZUVDTThhTURvcno2dHBsd0VmZVlXUjlBa3hscGswQ0FHRXhHQzZzdlhxdGk0c2wxZGMxRkNkejlLdm1jaE9ER3VtOTZiaXE2eGE4cFpiaTljS3dLclhqY0cyOE1ETlJ2Q3AwNWg1d3RMWHFTd25jcm1aNjlOYVhLSG5qX1EtVnl2N3oydDFpbmRjV0ppU1lwTkFFYzlxaG55Y1FZLUdlQ2tndG8zSHJYOV8wZjR4ZnVwYml2VjNTbUx5bWJfZmZySnV3ejU2OUpXSVBwMFpXRXM4RU5XdG5nS1lvbEsxdw?oc=5", "source_name": "Investing News Network", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics secures $135 million in private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNQnRsSU50ZUR1LXRSdnBQeV8yMl9tTjMtUlp4N0xfQWhyeXpKd1FqRlNWYmZCUEFfbDB1MEhiZFh3eWNhdG13ckdsbzV5cm51amhBOWlPZnV1Vm9OQ1BmSThTWUd6WktPb3NUdlVkdUVobWJVSUZBUi1FdDZtM29WdjJjWW1SbGllcjNNeVBDS0ZJMTB2RUhjT1ZTYS1OZVlxRWRlM25yT0I1c05jSUNhaWhpcTBIcHhDM1E?oc=5", "source_name": "Investing.com", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNTGh1Y1paWm1ycmFDX3dtazh2Tlo4cENibnBHd2dVRTBlekc4SXdNdVlNdWZJWDZHR2czdWxrTWwyZlVKZlFqbjJYQmwxRzlORUFodEs3MHB3VTRYTnNMM29TVnRSUFZIYUxyLXp4cmNtaEIwdUFrcWZ3U0JtZXNlVVZjNm1pdw?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics, Inc._December 31, 2024", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNUWQxUmtfNFg0bWpqR0RRMkc0Z0J5ckwyb1Y5UEk0MUhYXzJuSXpjck5meUhlQ2J1by1kMlI0NmRfdm1SazlORHpNYkdkcllOUVFpdDJRbkdTcG8zdGFFVldtSEVjZV93blFJTjNHNFVUenpRVHdfSWpfY3F6M0xnTDVZVkcwYWlaWG1mWHVpRDBMUQ?oc=5", "source_name": "SEC.gov", "published_at": "2025-03-21T00:59:10+00:00", "published_display": "21 Mar 2025 00:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics Raises $60 Million, Acquires Clade Therapeutics, and Expands Pipeline of Allogeneic, iPSC-Derived Cellular Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNM1Q2MTBxMzJUcTRZcF9HMTJlWGJ4alVDNXd1UWhTNWttMEdPU2s5dzRFcnBQWmxNQ05yT0dqMXlrLU1YQlZuaHoxODFfSkxIMW5aSGxCRlk0WlpjNXk2ZVZCWjRkMzV4U3VoODl4MTR3NUxnRlA5X0FESEk3QnpXV2dIYVBMQTjSAYwBQVVfeXFMTlNrTDVCdlpiQmxNM2xuOFBBT1hydEtMdDk2QzEycEhKZk41d1BBRGowSUxBTjdpM3haQWNGbnYtZlJETWwzLVNIeE1MRjhZSFpEcU5jNUtRQTdiYTE2VjZ4WnRJTnpPeWdJWUtmYTVsUy1pN1RFQ1JyaWc2M3k5VkNCYUVWZWhvckd6N3E?oc=5", "source_name": "BioInformant", "published_at": "2024-05-05T07:00:00+00:00", "published_display": "05 May 2024 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE1MRUNUeTBETy1xaWNWazJ0eHVURWdTYXVtMTVUNXlybVlmZjgtSjJHUkhzS01CdWpsY3NJTERHWUZPS1NJNVRUMTZveU9WOEU?oc=5", "source_name": "Zacks Investment Research", "published_at": "2021-06-21T01:51:48+00:00", "published_display": "21 Jun 2021 01:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Century Therapeutics (IPSC) Stock Price, News & Analysis $IPSC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBMNHhhMThYY2l6elk4Ykx1dzM2cHRGNHlwY0E4QXRRZXRGckFueDUwYUt2OU1uZGpXMklJZm0yNzJRRHFlUGY1WndLVl93UUNBcGVQLU55c09LZw?oc=5", "source_name": "MarketBeat", "published_at": "2021-06-19T00:01:24+00:00", "published_display": "19 Jun 2021 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 60, "sentiment_summary": {"positive": 13, "negative": 4, "neutral": 43, "score": 53, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 23.6, "count": 41}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 2.25, "latest_week": "2026-07-10", "one_week_move": -7.4, "four_week_move": 0.0, "twelve_week_move": -13.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.382485, "market_dynamics_buy_signal": false, "relative_strength": 37.473125, "fair_value_gap": 23.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 62.1421, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.4% over one week, +0.0% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 9}, {"label": "TradingView", "count": 6}, {"label": "Investing.com", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Seeking Alpha", "count": 2}, {"label": "Investing News Network", "count": 2}, {"label": "www.marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 41}, {"label": "Earnings", "count": 14}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-7.4% over one week, +0.0% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses"}], "updated_at": "2026-07-16T08:07:39.935034+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}